• news.cision.com/
  • Qlife Holding AB/
  • Qlife has been approved for listing on the Nasdaq First North Growth Market with first day of trading on March 2[nd,] 2020
English

Qlife has been approved for listing on the Nasdaq First North Growth Market with first day of trading on March 2[nd,] 2020

Report this content

Nasdaq Stockholm AB has approved the application of Qlife Holding AB (“Qlife”) for admission to trading of Qlife shares and TO1 series warrants on the Nasdaq First North Growth Market (“Nasdaq First North”). The first day of trading is set for March 2nd, 2020.

The short name for the Company’s shares on Nasdaq First North is QLIFE. The short name for the TO1 series warrants is QLIFE TO1.

Qlife has appointed G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

About Qlife

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

Subscribe